At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 63 enrolled
Drug / intervention
DaxibotulinumtoxinA for injectionbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy, Safety, and Duration of Benefit of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
In Brief
A Phase 2 clinical trial evaluating DaxibotulinumtoxinA for injection for Lateral Canthal Lines. Completed, enrolled 63 participants across 4 sites.
Detailed Summary
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Treatment of Moderate or Severe Lateral Canthal Lines (LCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLateral Canthal Lines
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartMar 2019
First PostedApr 2019
Primary CompletionApr 2020
TodayJul 2026
First PostedApr 10, 2019
Enrollment StartMar 11, 2019
Primary CompletionApr 23, 2020
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.2 years ago
Interventions
DaxibotulinumtoxinA for injectionbiological
Intramuscular injection